廣告
香港股市 已收市
  • 恒指

    18,608.94
    -259.77 (-1.38%)
     
  • 國指

    6,605.24
    -96.54 (-1.44%)
     
  • 上證綜指

    3,088.87
    -27.52 (-0.88%)
     
  • 滬深300

    3,601.48
    -40.32 (-1.11%)
     
  • 美元

    7.8123
    +0.0041 (+0.05%)
     
  • 人民幣

    0.9265
    -0.0004 (-0.04%)
     
  • 道指

    39,069.59
    +4.33 (+0.01%)
     
  • 標普 500

    5,304.72
    +36.88 (+0.70%)
     
  • 納指

    16,920.79
    +184.76 (+1.10%)
     
  • 日圓

    0.0495
    +0.0000 (+0.04%)
     
  • 歐元

    8.4741
    +0.0313 (+0.37%)
     
  • 英鎊

    9.9490
    +0.0370 (+0.37%)
     
  • 紐約期油

    77.80
    +0.93 (+1.21%)
     
  • 金價

    2,335.20
    -2.00 (-0.09%)
     
  • Bitcoin

    68,853.04
    +1,760.74 (+2.62%)
     
  • CMC Crypto 200

    1,440.81
    -27.29 (-1.86%)
     

Here's What Key Metrics Tell Us About Dentsply (XRAY) Q1 Earnings

For the quarter ended March 2024, Dentsply International (XRAY) reported revenue of $953 million, down 2.6% over the same period last year. EPS came in at $0.42, compared to $0.39 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $969.84 million, representing a surprise of -1.74%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.42.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

廣告

Here is how Dentsply performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Organic sales growth: -1.9% compared to the -0.5% average estimate based on five analysts.

  • Revenues- United States: $356 million compared to the $350.20 million average estimate based on three analysts. The reported number represents a change of +1.4% year over year.

  • Revenues- Rest of World: $221 million versus $231.08 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -4.3% change.

  • Revenues- Europe: $376 million compared to the $386.89 million average estimate based on three analysts. The reported number represents a change of -5.1% year over year.

  • Net sales- Connected Technology Solutions: $247 million compared to the $253.92 million average estimate based on five analysts. The reported number represents a change of -54.9% year over year.

  • Net sales- Wellspect Healthcare: $71 million versus $71.80 million estimated by five analysts on average.

  • Net sales- Essential Dental Solutions: $364 million compared to the $377.32 million average estimate based on five analysts.

  • Net sales- Orthodontic and Implant Solutions: $271 million versus the five-analyst average estimate of $266.79 million.

  • Adjusted Operating Income- Connected Technology Solutions: $2 million versus $21.25 million estimated by two analysts on average.

  • Adjusted Operating Income- Wellspect Healthcare: $23 million versus the two-analyst average estimate of $19.39 million.

  • Adjusted Operating Income- Orthodontic and Implant Solutions: $42 million versus $42.40 million estimated by two analysts on average.

  • Adjusted Operating Income- Essential Dental Solutions: $115 million versus $124.87 million estimated by two analysts on average.

View all Key Company Metrics for Dentsply here>>>

Shares of Dentsply have returned -5.2% over the past month versus the Zacks S&P 500 composite's -4.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research